BMS creates global cancer drug collaboration

Looking to build on its arsenal of drugs that harness the human immune system to fight cancer, Bristol-Myers Squibb ($BMY) has created a global network of investigators at top research institutions around the globe to collaborate on the development of new therapies that can be pushed into the clinic. Investigators from the Dana-Farber Cancer Institute will join forces with France's Institut Gustave Roussy and others to work on the translational effort. "The International Immuno-Oncology Network facilitates a public-private partnership that will leverage intellectual capabilities across a global network," said Elliott Sigal, executive vice president, chief scientific officer and president, R&D, for Bristol-Myers Squibb. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.